Sentinel Lymph Node Biopsy Was Associated With Favorable Survival Outcomes For Patients With Clinically Node-Negative Asian Melanoma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1 ):11–30. doi:10.3322/caac.2116623335087
   PubMed Web of Science ®Google Scholar
• Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1 ):51–65. doi:10.1056/NEJMra05216616822996
   PubMed Web of Science ®Google Scholar
• Ishihara K, Saida T, Yamamoto A. Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol. 2001;6(3 ):109–116. doi:10.1007/PL0001209111706778
   PubMedGoogle Scholar
• Lee MW, Koh JK, Kwon KS, et al. Clinical and histopathological study of cutaneous melanoma in Korea. Korean J Dermatol. 2003;41(1 ):43–47.
   Google Scholar
• Chang JWC, Yeh KY, Wang CH, et al. Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res. 2004;14(6 ):537–541. doi:10.1097/00008390-200412000-0001615577327
   PubMed Web of Science ®Google Scholar
• Luk N, Ho L, Choi C, Wong K, Yu K, Yeung W. Clinicopathological features and prognostic factors of cutaneous melanoma among Hong Kong Chinese. Clin Exp Dermatol. 2004;29(6 ):600–604. doi:10.1111/ced.2004.29.issue-615550131
   PubMed Web of Science ®Google Scholar
• Wu CE, Hsieh CH, Chang CJ, et al. Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy. J Formos Med Assoc. 2013;114:415–421.23969039
   PubMed Web of Science ®Google Scholar
• Liu XK, Li J. Acral lentiginous melanoma. Lancet. 2018;391(10137 ):e21. doi:10.1016/S0140-6736(18)31071-7
   PubMed Web of Science ®Google Scholar
• Jung HJ, Kweon -S-S, Lee J-B, Lee S-C, Yun SJ. A clinicopathologic analysis of 177 acral melanomas in koreans: relevance of spreading pattern and physical stress. JAMA Dermatol. 2013;149(11 ):1281–1288. doi:10.1001/jamadermatol.2013.585324067997
   PubMed Web of Science ®Google Scholar
• Sheen YS, Liao YH, Lin MH, et al. A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress. Sci Rep. 2017;7(1 ):5564.28717212
   PubMedGoogle Scholar
• Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145(4 ):427–434. doi:10.1001/archdermatol.2008.60919380664
   PubMedGoogle Scholar
• Chang JW, Guo J, Hung CY, et al. Sunrise in melanoma management: time to focus on melanoma burden in Asia. Asia Pac J Clin Oncol. 2017;13(6 ):423–427. doi:10.1111/ajco.1267028198155
   PubMed Web of Science ®Google Scholar
• Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4 ):392–399. doi:10.1001/archsurg.1992.014200400340051558490
   PubMed Web of Science ®Google Scholar
• Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220(6 ):759–767. doi:10.1097/00000658-199412000-000097986143
   PubMed Web of Science ®Google Scholar
• Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009;60(5 ):872–875. doi:10.1016/j.jaad.2008.09.06719389531
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7 ):599–609. doi:10.1056/NEJMoa131046024521106
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13 ):1307–1317. doi:10.1056/NEJMoa06099217005948
   PubMed Web of Science ®Google Scholar
• Thomas JM. Sentinel-node biopsy in melanoma. N Engl J Med. 2007;356(4 ):418;author reply 419–421.
   PubMedGoogle Scholar
• Gershenwald JE, Ross MI. Is sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol. 2007;4(5 ):278–279. doi:10.1038/ncponc079117389881
   PubMedGoogle Scholar
• Torjesen I. Sentinel node biopsy for melanoma: unnecessary treatment? BMJ. 2013;346:e8645. doi:10.1136/bmj.e864523299845
   PubMedGoogle Scholar
• Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19 ):1813–1823. doi:10.1056/NEJMoa170853928891408
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19 ):1824–1835. doi:10.1056/NEJMoa170903028891423
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Robert C, Suciu S. Adjuvant pembrolizumab in resected stage III melanoma. N Engl J Med. 2018;379(6 ):593–595.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8 ):2105–2110. doi:10.1245/s10434-018-6513-729850954
   PubMed Web of Science ®Google Scholar
• Liu SH, Chang WC, Kao PF, et al. Lymphoscintigraphy and intraoperative gamma probe-directed sentinel lymph node mapping in patients with malignant melanoma. J Formos Med Assoc. 2004;103(1 ):41–46.15026857
   PubMed Web of Science ®Google Scholar
• Uhara H, Takata M, Saida T. Sentinel lymph node biopsy in Japan. Int J Clin Oncol. 2009;14(6 ):490–496. doi:10.1007/s10147-009-0941-019967483
   PubMed Web of Science ®Google Scholar
• Noro S, Yamazaki N, Nakanishi Y, Yamamoto A, Sasajima Y, Kawana S. Clinicopathological significance of sentinel node biopsy in Japanese patients with cutaneous malignant melanoma. J Dermatol. 2011;38(1 ):76–83. doi:10.1111/jde.2010.38.issue-121175760
   PubMed Web of Science ®Google Scholar
• Ito T, Moroi Y, Oba J, et al. The prognostic value of a reverse transcriptase-PCR assay of sentinel lymph node biopsy for patients with cutaneous melanoma: a single-center analysis in Japan. Melanoma Res. 2012;22(1 ):38–44. doi:10.1097/CMR.0b013e32834dcfdf22108607
   PubMed Web of Science ®Google Scholar
• Namikawa K, Yamazaki N, Nakai Y, et al. Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: a multi-institutional study of 450 patients in Japan. J Dermatol. 2012;39(2 ):130–137. doi:10.1111/jde.2012.39.issue-221950448
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7(2 ):87–97. doi:10.1007/s10434-000-0087-910761786
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med. 2014;370(7 ):663–664. doi:10.1056/NEJMe131369024521113
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New Engl J Med. 2017;377(14 ):1345–1356. doi:10.1056/NEJMoa170968428889792
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4 ):582–588. doi:10.1093/annonc/mdz01130715153
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626–636. doi:10.1056/NEJMoa190405931166680
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19 ):1789–1801. doi:10.1056/NEJMoa180235729658430
   PubMed Web of Science ®Google Scholar